Since ATM and CK1 synergistically control β-TRCP-mediated Mdm2 ubiquitination and destruction, our work provides a rational for the use of CKI and/or ATM agonists as anti-cancer agents to promote Mdm2 destruction, which might improve the overall survival of patients diagnosed with cancer in the future. Here, MDM2 is linked to cancer.